Correlation of clinicopathological features and tumor response to HPE therapy of gastric DLBCL
| Clinicopathological characteristics . | Tumors response to HPE . | ||
|---|---|---|---|
| HP dependent, n = 35 . | HP independent, n = 28 . | P . | |
| Age (median, range), y | 61 (34-88) | 60 (21-87) | .891* |
| Sex, male/female | 11/24 | 13/15 | .223† |
| Endoscopic features, n (%) | .033‡ | ||
| Gastritis-like or multiple erosion on infiltrative mucosa | 13 (37.2) | 6 (21.4) | |
| Ulceration or ulcerated mass | 20 (57.1) | 15 (53.6) | |
| Erosions on giant nodular folds | 2 (5.7) | 7 (25.0) | |
| Location of tumor(s), n (%) | .025† | ||
| Proximal§ or ≥2 components | 8 (22.9) | 14 (50.0) | |
| Distal|| | 27 (77.1) | 14 (50.0) | |
| Depth of gastric wall involvement, n (%)¶ | .022† | ||
| Submucosa or above | 15/31 (48.4) | 5/26 (19.2) | |
| Muscularis propria or beyond | 16/31 (51.6) | 21/26 (80.8) | |
| Histology, n (%) | .473† | ||
| DLBCL (MALT) | 22 (62.9) | 20 (71.4) | |
| Pure DLBCL | 13 (37.1) | 8 (28.6) | |
| CagA expression, n (%) | <.001† | ||
| Negative | 9 (25.7) | 21 (75.0) | |
| Positive | 26 (74.3) | 7 (25.0) | |
| p-SHP2 expression, n (%)# | .001† | ||
| Negative | 7/28 (25.0) | 18/25 (72.0) | |
| Positive | 21/28 (75.0) | 7/25 (28.0) | |
| p-ERK expression, n (%)# | .004† | ||
| Negative | 6/28 (21.4) | 15/25 (60.0) | |
| Positive | 22/28 (78.6) | 10/25 (40.0) | |
| BCL10 expression, n (%) | <.001† | ||
| Cytoplasmic/negative | 33 (94.3) | 7 (25.0) | |
| Nuclear | 2 (5.7) | 21 (75.0) | |
| NF-κB (p65) expression, n (%) | <.001† | ||
| Cytoplasmic/negative | 31 (88.6) | 9 (32.1) | |
| Nuclear | 4 (11.4) | 19 (67.9) | |
| BAFF expressions, n (%) | <.001† | ||
| Negative | 30 (85.7) | 12 (42.9) | |
| Positive | 5 (14.3) | 16 (57.1) | |
| CD86 expressions, n (%) | <.001† | ||
| Negative | 13 (37.1) | 23 (82.1) | |
| Positive | 22 (62.9) | 5 (17.9) | |
| Clinicopathological characteristics . | Tumors response to HPE . | ||
|---|---|---|---|
| HP dependent, n = 35 . | HP independent, n = 28 . | P . | |
| Age (median, range), y | 61 (34-88) | 60 (21-87) | .891* |
| Sex, male/female | 11/24 | 13/15 | .223† |
| Endoscopic features, n (%) | .033‡ | ||
| Gastritis-like or multiple erosion on infiltrative mucosa | 13 (37.2) | 6 (21.4) | |
| Ulceration or ulcerated mass | 20 (57.1) | 15 (53.6) | |
| Erosions on giant nodular folds | 2 (5.7) | 7 (25.0) | |
| Location of tumor(s), n (%) | .025† | ||
| Proximal§ or ≥2 components | 8 (22.9) | 14 (50.0) | |
| Distal|| | 27 (77.1) | 14 (50.0) | |
| Depth of gastric wall involvement, n (%)¶ | .022† | ||
| Submucosa or above | 15/31 (48.4) | 5/26 (19.2) | |
| Muscularis propria or beyond | 16/31 (51.6) | 21/26 (80.8) | |
| Histology, n (%) | .473† | ||
| DLBCL (MALT) | 22 (62.9) | 20 (71.4) | |
| Pure DLBCL | 13 (37.1) | 8 (28.6) | |
| CagA expression, n (%) | <.001† | ||
| Negative | 9 (25.7) | 21 (75.0) | |
| Positive | 26 (74.3) | 7 (25.0) | |
| p-SHP2 expression, n (%)# | .001† | ||
| Negative | 7/28 (25.0) | 18/25 (72.0) | |
| Positive | 21/28 (75.0) | 7/25 (28.0) | |
| p-ERK expression, n (%)# | .004† | ||
| Negative | 6/28 (21.4) | 15/25 (60.0) | |
| Positive | 22/28 (78.6) | 10/25 (40.0) | |
| BCL10 expression, n (%) | <.001† | ||
| Cytoplasmic/negative | 33 (94.3) | 7 (25.0) | |
| Nuclear | 2 (5.7) | 21 (75.0) | |
| NF-κB (p65) expression, n (%) | <.001† | ||
| Cytoplasmic/negative | 31 (88.6) | 9 (32.1) | |
| Nuclear | 4 (11.4) | 19 (67.9) | |
| BAFF expressions, n (%) | <.001† | ||
| Negative | 30 (85.7) | 12 (42.9) | |
| Positive | 5 (14.3) | 16 (57.1) | |
| CD86 expressions, n (%) | <.001† | ||
| Negative | 13 (37.1) | 23 (82.1) | |
| Positive | 22 (62.9) | 5 (17.9) | |
P values (2-sided) were calculated using the Student t test.
P values (2-sided) were calculated using the χ2 test or the Fisher exact test.
P values (2-sided) were calculated using 1-way analysis of variance.
Proximal: Middle body, upper body, fundus, or cardia.
Distal: Antrum, angle, or lower body.
Gastric wall involvement was evaluated by endoscopic ultrasonography in 57 patients.
Fifty-three cases with available tissue specimens for assessment of expression patterns of p-SHP-2 and p-ERK by immunohistochemical staining.